Major pharmaceutical companies are attempting to limit the economic damage from a new U.S. insurer tactic that helps patients avoid expensive drugs, according to Reuters. The maneuver by insurers is forcing drug makers to assist patients with their copays causing a decline in U.S. drug prices. Pharmaceutical companies are trying to battle the insurers by including new payment options to evade detection from copay accumulators and taking tougher stances in pricing negotiations. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY), AbbVie (ABBV), Amgen (AMGN) and Sanofi (SNY).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.